ClinicalTrials.gg
RecruitingNCT03844360Updated Mar 30, 2025

Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

A Phase 4 interventional study of Bortezomib and Eltrombopag in Hematological Neoplasms, sponsored by Wei Zhao. Recruiting at 2 sites in China. Open to participants aged 1 Day to 18 Years. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by Wei Zhao · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Registered 3 years after the study started (first participant enrolled Jan 2016, registered Feb 2019).
  • Started Jan 2016; still recruiting 10 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,500
Allocation
Not applicable
Ages
1 Day to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing bortezomib in Hematologic Neoplasms — 3 open to participants now, 3 under way, 1 of them phase 3. Bortezomib · Hematologic Neoplasms.

Planned enrollment
Largest of 10
1,500 · median 41
Started
2016
with 1 other
Phase 4
Only one
of the 10
Registered
8th of 10
by date
Lead sponsor
1 of 10
Wei Zhao

Among the 10 studies testing bortezomib in Hematologic Neoplasms, this one has the largest planned enrollment, is one of 2 that started in 2016, is the only one in phase 4, and was the 8th registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

3 of the 10 studies testing bortezomib in Hematologic Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About bortezomib

Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 1 Day to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing bortezomib in Hematologic Neoplasms, or all of them as a file.
02

Study summary

The investigators' purpose was to assess the feasibility of dosage individualization of the commonly used antineoplastic drugs and anti-infective drugs in children with hematoplastic disease.

Read the detailed description

The investigators' purpose was to assess the feasibility of dosage individualization of the commonly used antineoplastic drugs and anti-infective drugs based on the opportunistic sampling strategy in children with confirmed or suspected hematological neoplasms.

03

Conditions studied

  • Hematological Neoplasms
04

Who can participate

Ages eligible
1 Day to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must be diagnosed with hematological neoplasms
  • Antineoplastic drugs or anti-infective drugs used as part of regular treatment

Exclusion criteria

Exclusion Criteria:

  • expected survival time less than the treatment cycle;
  • patients with other factors that researcher considers unsuitable for inclusion.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,500 participants (estimated)

Study arms

  • Experimental
    Antineoplastic Drugs and Anti-infective Drugs

    Bortezomib;eltrombopag;imatinib;dasatinib, pegaspargase and anti-infective drugs administered at standard dose for children with hematological neoplasms.

    Drug: Bortezomib · Drug: Eltrombopag · Drug: Imatinib · Drug: dasatinib · Drug: Pegaspargase · Drug: Anti-Infective Drugs · Drug: PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor

Interventions

  • bortezomib was administered follow the doctor's advice.

    Also known as: Velcade

  • eltrombopag was administered follow the doctor's advice.

    Also known as: promacta

  • imatinib was administered follow the doctor's advice.

    Also known as: Gleevec

  • dasatinib was administered follow the doctor's advice.

    Also known as: sprycel

  • pegaspargase was administered follow the doctor's advice.

    Also known as: Oncaspar

  • DrugAnti-Infective Drugs

    anti-infective drugs was administered follow the doctor's advice.

  • DrugFilgrastimStudies of FilgrastimFilgrastim pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    pegaspargase was administered follow the doctor's advice.

    Also known as: PEG-rhG-CSF

06

What researchers measure

Primary outcomes

  1. change of plasma concentration of bortezomib

    To detect the plasma concentrations of bortezomib after administration

    Time frame: at(0-0.5)h,(0.5-3)h,(24-48)h,(48-72)h hours after administration

  2. change of plasma concentration of eltrombopag

    To detect the plasma concentrations of eltrombopag after administration

    Time frame: at (0.5-3)h,(3-6)h,(10-14)h,(20-24)h hours after oral administration

  3. change of plasma concentration of imatinib

    To detect the plasma concentrations of imatinib after administration

    Time frame: at (0.5-2)h,(2-4)h,(10-14)h,(20-24)h hours after oral administration

  4. change of plasma concentration of dasatinib

    To detect the plasma concentrations of dasatinib after administration

    Time frame: at(0-0.5)h,(0.5-3)h,(10-14)h,(20-24)h hours after oral administration

  5. change of plasma concentration of pegaspargase

    To detect the plasma concentrations of pegaspargase after administration

    Time frame: at Day-1,Day(0-1),Day(3-5),Day(8-10),Day(13-14) after administration

  6. plasma concentration of anti-infective drug

    To detect the plasma concentrations of anti-infective drug after administration

    Time frame: through study completion, an average of 14 days

07

Study locations

1 of 2 sites recruiting
  • Department of Pediatrics, the Affiliated Hospital of Xuzhou Medical University
    Xuzhou, Jiangsu 221000, China
    Completed

    Not enrolling at this site.

  • State Key Laboratory of Experimental Haematology, Department of Paediatric Haematology, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
    Tanjin, Tianjin 300020, China
    Recruiting
08

References and documents

Publications

  • Yang F, Zhang L, Zhao BB, Zhang JL, Liu XT, Li X, Tang BH, Zhou Y, Yang XM, van den Anker J, Zhu XF, Zhao W. Population Pharmacokinetics and Safety of Dasatinib in Chinese Children with Core-Binding Factor Acute Myeloid Leukemia. Clin Pharmacokinet. 2022 Jan;61(1):71-81. doi: 10.1007/s40262-021-01054-6. Epub 2021 Jul 9. PubMed 34240339 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2016 (actual). Primary completion is estimated for Dec 2025, 119 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2019
First posted
Feb 18, 2019
StartActual
Jan 31, 2016
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2026
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03844360
Lead sponsor
Wei Zhao
Responsible party
Wei Zhao (Professor; Head of department of clinical pharmacy and pharmacology, Shandong University) — Sponsor-investigator
First posted
Feb 18, 2019
Start date
Jan 31, 2016
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 30, 2025

Study contacts

Wei Zhao, Ph.D
Contact
zhao4wei2@hotmail.com
86053188383308
Yan H Shi, Ph.D
Contact
zhao4wei2@hotmail.com
86053188383308
Wei Zhao, Ph.D
principal investigator · Shandong University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bortezomib · Eltrombopag · Imatinib · Dasatinib · Pegaspargase · Filgrastim

Start the discussion